Eli Lilly (LLY) Restructuring Costs (2009 - 2026)

Eli Lilly (LLY) has reported Restructuring Costs for 18 consecutive years, with $279.0 million the latest figure, recorded in Q1 2026.

• Restructuring Costs for Q1 2026 came in at $279.0 million, up 697.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $728.0 million (down 18.75% YoY), and the FY2025 annual result was $484.0 million, down 43.79% from the prior year.
• Restructuring Costs was $279.0 million for Q1 2026 at Eli Lilly, up from $84.1 million in the prior quarter.
• Over five years, Restructuring Costs peaked at $435.0 million in Q2 2024 and troughed at $35.0 million in Q1 2025.
• Average Restructuring Costs over 5 years is $193.7 million, with a median of $145.3 million recorded in 2022.
• Year-over-year, Restructuring Costs slumped 75.58% in 2025 and soared 697.14% in 2026.
• Over 5 years, Restructuring Costs stood at $38.1 million in 2022, then jumped by 78.48% to $68.0 million in 2023, then jumped by 406.47% to $344.4 million in 2024, then plunged by 75.58% to $84.1 million in 2025, then jumped by 231.75% to $279.0 million in 2026.
• Per Business Quant data, the three most recent Restructuring Costs figures were $279.0 million in Q1 2026, $84.1 million in Q4 2025, and $364.9 million in Q3 2025.